APA (7th ed.) Citation

SH, K., R, F., G, S., C, M., S, A., CJ, E., . . . G, G. (2023). Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): A randomised, placebo-controlled, double-blind, phase 2 trial. The Lancet. Infectious diseases, 23(2), 183. https://doi.org/10.1016/S1473-3099(22)00644-2

Chicago Style (17th ed.) Citation

SH, Khoo, et al. "Molnupiravir Versus Placebo in Unvaccinated and Vaccinated Patients with Early SARS-CoV-2 Infection in the UK (AGILE CST-2): A Randomised, Placebo-controlled, Double-blind, Phase 2 Trial." The Lancet. Infectious Diseases 23, no. 2 (2023): 183. https://doi.org/10.1016/S1473-3099(22)00644-2.

MLA (9th ed.) Citation

SH, Khoo, et al. "Molnupiravir Versus Placebo in Unvaccinated and Vaccinated Patients with Early SARS-CoV-2 Infection in the UK (AGILE CST-2): A Randomised, Placebo-controlled, Double-blind, Phase 2 Trial." The Lancet. Infectious Diseases, vol. 23, no. 2, 2023, p. 183, https://doi.org/10.1016/S1473-3099(22)00644-2.